Blog

Iora Health Raises $100 Million in Series E Financing

BOSTON, May 21, 2018 /PRNewswire/ — Iora Health, a high-growth, value based primary care provider with a focus on Medicare patients over 65 years of age, announced today that it has secured $100 million in funding to support continued growth and improved technology. The Series E financing is funded by global investors including .406 Ventures, Devonshire Investors, F-Prime Capital, Flare Capital Partners, GE Ventures, Humana, Khosla Ventures, Polaris Partners and Temasek.

 Iora Health currently serves patients across the country with a high impact, relationship-based care model that is provento delight patients, improve health, and reduce costs.

“Last year we doubled our number of patients, and we are on track to do the same this year. Iora’s vision since our inception has been to transform health care. To have truly transformative impact, we must continue to grow and care for more patients,” said Rushika Fernandopulle, Co-Founder and CEO of Iora Health. “With the support of our investors, this new funding will allow us to deliver our high quality care to more patients in new and existing markets.”

Read more

Protenus Recognized as One of the Best Places to Work in Healthcare in 2018

CHICAGO — Protenus has been selected by Modern Healthcare as one of the 2018 Best Places to Work in Healthcare. The complete list of this year’s winners, in alphabetical order, is available here. Modern Healthcare will publish a special supplement featuring ranked lists of all the winners along with the October 1 issue.

“Whether on the frontline or in the top office, healthcare employees witness moments that can either inspire or dishearten them. That can take a toll on an individual and healthcare organizations must take extra steps to ensure that highs and lows during the workday don’t impact engagement or performance,” said Modern Healthcare Editor Aurora Aguilar. “This year’s best places to work, voted on by the employees themselves, exemplify what it takes to maintain dedication and satisfaction among its employees and that is the key to good patient care. Congratulations to this year’s winners and we look forward to celebrating with you in September.”

Read More

Innovent Biologics Announces the Study Result of its Anti-PD-1 Antibody in Hodgkin Lymphoma

SUZHOU, China — Innovent Biologics (Suzhou) Co. Ltd. (Innovent Biologics) today announced the findings from the ORIENT-1 trial investigating Sintilimab, the company’s fully human anti-PD-1 therapy (IBI308), in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL). The preliminary result of the ORIENT-1 trial was published at ASCO’s official website on May 16, 2018. The updated and final analysis on its primary endpoint mentioned in this press release will be presented at the 2018 ASCO Annual Meeting in Chicago in a poster session on Saturday, June 4, 2018.

ORIENT-1 is a multicenter, single-arm, phase 2 registrational study assessing the efficacy and safety profile of IBI308. A total of ninety-six patients with r/r cHL were enrolled. It is the largest study for this indication in China.

The primary endpoint is objective response rate (ORR), defined as the percentage of study subjects who either experienced a partial response (PR) or a complete response (CR), which was assessed by independent radiographic review committee (IRRC) according to the revised international working group response criteria for malignant lymphoma in 2007 (IWG 2007). Complete response rate (CR) is a secondary endpoint.

Read More

Turnstone Biologics Announces U.S. FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers

NEW YORK & OTTAWA, Ontario–(BUSINESS WIRE)–May 16, 2018–Turnstone Biologics today announced it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug Application (IND) for MG1-HPV for the treatment of patients with human papillomavirus (HPV) positive solid tumors. Additionally, Turnstone today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (“Roche”) under which Roche will provide atezolizumab (Tecentriq ® ), its anti-PDL1 antibody, for use in combination with Turnstone’s Maraba virus immunotherapy platform, MG1.

Turnstone will investigate the safety and efficacy of MG1-HPV therapy in combination with atezolizumab across a range of HPV positive tumors in a Phase I/II clinical study expected to commence in the second quarter of 2018.

 Read more

 

TraceLink Achieves 69% Overall Revenue Growth in Q1 2018, Including 270% Revenue Growth in EMEA

NORTH READING, Mass. — TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the first quarter of 2018.

Financial growth highlights for Q1 2018 include:

•A 69 percent year-over-year increase in Q1 revenue, including revenue growth in the following regions:
◦386 percent revenue growth in APAC;
◦270 percent revenue growth in EMEA; and,
◦159 percent revenue growth in India.

•A 43 percent year-over-year increase in all bookings for Q1, including a 177 percent increase in EMEA bookings for the quarter;
•A two-year revenue compound annual growth rate (CAGR) of 70 percent; and,
•A 38 percent annual increase in customers for a total of 821 customers across 35 countries, demonstrating the largest customer base for pharmaceutical track and trace and serialization, spanning all segments within the global life sciences supply chain, including:

Read More

Kensho Technologies, Acquired by S&P Global, Hits Early Milestone; Expands Private Company Data Offering to Clients

NEW YORK — S&P Global announced today that the Company has hit an exciting milestone in an alternative data linking project in collaboration with Kensho Technologies Inc. (“Kensho”), acquired by SPGI in April, and Crunchbase, a well-known destination for data on some the world’s most innovative companies. Leveraging Kensho’s machine learning algorithms, S&P Global Market Intelligence platform users can now access robust information on privately held companies licensed from Crunchbase.

“The Private Company Data space is an area of enormous growth and of high value to many of our clients who are particularly interested in being able to identify early stage, venture backed companies prime for acquisition or investment,” noted Mike Chinn, Executive Vice President of Data and Technology Innovation at S&P Global and President of S&P Global Market Intelligence. “Given the complexity and opaqueness of this data, we had originally expected project completion to take several months. I’m thrilled that in less than a month after our acquisition of Kensho, S&P Global has already hit this major milestone, strengthening our ability to meet the demand of clients at an accelerated pace as we become the go-to resource for comprehensive private company data.”

Read More

Beam Therapeutics Launched to Develop Harvard Base Editing Technology toward Precision Genetic Medicines

Harvard innovations enable the correction of single-base mutations in DNA with unprecedented precision and efficiency

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Harvard University has granted a worldwide license to Beam Therapeutics, Inc., to develop and commercialize a suite of revolutionary DNA base editing technologies for the treatment of human disease.

The versatile platform of base editing technologies was invented by David R. Liu, PhD, Professor of Chemistry and Chemical Biology, and visionary postdoctoral fellows and graduate students in his Harvard laboratory.

“We developed programmable molecular machines that go to a target site of our choosing in the genomic DNA of a cell and directly convert one base to another base without making a double-stranded break in the DNA,” said Liu, who is a cofounder of Beam.

Read more

Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as Chief Executive Officer and President

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointment of Bastiano Sanna, Ph.D., as Chief Executive Officer and President. Dr. Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the Interim CEO and will remain as an advisor to the Company.

“Bastiano has the perfect set of skills and experiences to lead Semma through our next phase of growth as a company after a very successful Series B financing,” said Mark Fishman, M.D., Chairman of Semma’s Board of Directors. “Few leaders have such a strong cell therapy background combined with his level of strategic and business experience.”

Read more

Ivenix to Showcase Patient-Centered Infusion System at NTI 2018

BOSTON — Ivenix, a medical technology company with the vision of eliminating infusion-related patient harm, today announced it will showcase its innovative infusion system and offer continuing education sessions at the 2018 National Teaching Institute (NTI) and Critical Care Exposition, which takes place from May 21 to May 24 in Boston.

Infusion-related errors are responsible for 54 percent of the approximately 1.5 million adverse drug events reported to the U.S. Food and Drug Administration (FDA) annually. Sixty-one percent of those adverse events are reported to be serious or life-threatening. The Ivenix Infusion System includes a large volume infusion pump with intuitive infusion delivery designed to inform clinical workflow, enhance patient experience and help improve patient safety.

Ivenix will host the following 30-minute continuing education sessions during the NTI ExpoEd at Booth 1905.

Read More

New England Venture Capital Association names 2018 NEVY Awards winners – Devoted Health named Healthcare IT Company of the Year

The New England Venture Capital Association named the winners of the 2018 NEVY Awards Wednesday night at a Star Wars-themed event at the House of Blues in Boston.

The awards honor both startups and investors in tech and life sciences. This year’s winners included Desktop Metal, the 3D-printing startup that flew to unicorn status in 2017 after only 21 months in business.

See the full list of winners below and the nominees here.

Read more